Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P-RAD: Preoperative Chemotherapy, Pembrolizumab and Radiation in Node-Positive, HER2-Negative Breast Cancer
NCT04443348Phase 2Active, not recruiting
- Sponsor
- Laura M. Spring
- Start
- Dec 2020
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in breast cancer (3 arms), sponsored by Laura M. Spring. Primary endpoints: Tumor Infiltrating Lymphocytes and Rate of pathologic response in the lymph node at 7 months. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04443348.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04443348.